关于持股 5%以上股东减持股份的预披露公告 证券代码：300347 证券简称：泰格医药 公告编码（2025）032 号 杭州泰格医药科技股份有限公司 公司持股 5%以上股东曹晓春女士保证向公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 杭州泰格医药科技股份有限公司（以下简称"公司"或"泰格医药"）于近日收到公司持 股5%以上股东、董事及总经理曹晓春女士关于计划减持公司股份的告知函：曹晓春女士 持有本公司股份51,661,774股（占剔除回购专户股份数后公司总股本的6.0413%，占公司 A股总股本的7.0575%），计划自本公告披露之日起15个交易日之后的3个月内（窗口期不 减持）以集中竞价和/或大宗交易方式减持公司股份不超过3,000,000股（占剔除回购专户 股份数后公司总股本的0.3508%，占公司A股总股本的0.4098%）。 现将相关事项公告如下： 一、股东的基本情况 | | | | 占剔除回购专户股 | 占剔除回购专户股 | | --- | --- | --- | --- | --- | | ...

Investment Rating - The report maintains a positive outlook on innovative drugs and the industry chain, recommending continuous attention to this sector [1][5][24]. Core Viewpoints - The report highlights the sustained high prosperity of innovative drugs, with a focus on companies likely to see a revaluation, such as Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, and Huadong Medicine. It also emphasizes Biopharma/Biotech companies with innovative pipelines entering a growth phase, including PATEO, Innovent Biologics, BeiGene, and others [1][5][24]. - The A-share pharmaceutical sector outperformed the market in the third week of July 2025, with a 4.0% increase compared to a 0.7% rise in the Shanghai Composite Index. The report notes that the premium of the pharmaceutical sector relative to all A-shares is currently at a normal level of 86.8% [7][25][16]. - The Hong Kong pharmaceutical sector showed outstanding performance, with the Hang Seng Healthcare index rising by 12.0% and the Hong Kong Biotechnology index increasing by 13.6% during the same period [21][25]. Summary by Sections 1. Continuous Focus on Innovative Drugs and Industry Chain - The report emphasizes the ongoing high demand for innovative drugs and recommends companies such as Heng Rui Medicine, Hansoh Pharmaceutical, and others for potential investment [1][5][24]. 2. Performance of A-Shares Pharmaceutical Sector - In the third week of July 2025, the A-share pharmaceutical sector led with a 4.0% increase, outperforming the overall market. Notable sub-sectors included chemical raw materials and chemical preparations, with gains of 7.0% and 6.8% respectively [7][11][25]. 3. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong pharmaceutical sector performed exceptionally well, with significant gains in the Hang Seng Healthcare and Biotechnology indices. In contrast, the U.S. pharmaceutical sector underperformed, with a decline of 2.5% in the S&P 500 Healthcare Select Sector [21][25].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [1][40]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 7.84% from July 11 to July 24, 2025, exceeding the CSI 300's performance by approximately 4.13 percentage points [4][14]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and raw materials sectors leading with increases of 14.23% and 9.30%, respectively [4][15]. - Approximately 91% of stocks in the industry achieved positive returns, with notable performers including Borui Pharmaceutical, which saw a weekly increase of 78.98% [16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 7.84% from July 11 to July 24, 2025, surpassing the CSI 300 by about 4.13 percentage points [14]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and raw materials, which increased by 14.23% and 9.30%, respectively [15]. - About 91% of stocks in the industry had positive returns, with Borui Pharmaceutical leading at 78.98% [16]. 2. Industry News - The report highlights the ongoing progress of the 11th batch of national drug procurement, with significant updates provided during a government open day event on July 22, 2025 [4][28]. - The announcement of the 11th batch of national drug procurement included a notification for drug information submission, which was highly anticipated [4][28]. 3. Company Announcements - Yekang Pharmaceutical announced that its subsidiary received FDA approval for clinical trials of YKYY029 injection for hypertension treatment [29]. 4. Industry Outlook - The report maintains an "Overweight" rating for the industry, citing a continuous rise in the pharmaceutical and biotechnology sector driven by positive sentiment towards innovative drugs and improved financing data [30]. - The report suggests focusing on investment opportunities within the innovative drug supply chain and highlights several companies across various segments, including medical devices, pharmaceutical commerce, and innovative drugs [30][32].

Group 1: Market Performance - The pharmaceutical sector showed strength in early trading on July 25, with the Biopharmaceutical ETF (159859) having a turnover rate exceeding 3.5% and a transaction volume of over 1.11 billion yuan, leading among its peers [1] - The Medical Devices ETF (159873) increased by 0.82% with a turnover rate over 8.1%, featuring stocks like Kangtai Medical hitting the daily limit [1] - The Innovation Drug ETF Tianhong (517380) rose by 0.79% with a turnover rate exceeding 1.8%, and its constituent stocks included Kanglong Chemical and WuXi Biologics, which saw significant gains [1] Group 2: ETF Characteristics - The Biopharmaceutical ETF (159859) closely tracks the National Index of Biopharmaceuticals (399441.SZ), covering various sectors such as innovative drugs, CXO, vaccines, and blood products, making it the largest and most liquid product in its category [1] - The Innovation Drug ETF Tianhong (517380) is the largest in the market, spanning the Shanghai, Shenzhen, and Hong Kong markets, and is the only ETF tracking the Hang Seng Shanghai-Shenzhen-Hong Kong Innovation Drug Select 50 Index, which has a cumulative weight of nearly 60% in its top ten constituents [2] Group 3: Industry Insights - Jianghai Securities emphasizes the importance of focusing on innovative drug companies with rich R&D pipelines and suggests investing in the entire innovative drug industry chain due to its potential for strong synergistic development [3] - Everbright Securities recommends focusing on two types of targets: those that have consistently been selected in centralized procurement and possess dual advantages in quality and cost, and innovative drug companies with rich R&D pipelines whose core products are entering medical insurance or are expected to be included in the innovative drug catalog [3]

Group 1 - US stock indices showed mixed performance, with the Chinese concept index down by 1.54%. Hong Kong's three major indices opened lower, with the Hang Seng Index down 0.53% and the Hang Seng Tech Index down 0.51% [1] - CXO concept stocks in Hong Kong saw initial gains, with Kanglong Chemical rising over 10%, and other companies like WuXi Biologics and Tigermed also experiencing significant increases [1] - The Hang Seng Medical ETF (513060) opened high and saw a nearly 2% increase, with active trading and a turnover of nearly 800 million yuan, indicating strong investor interest [1] Group 2 - CXO industry leaders are showing signs of stabilization, with expectations for marginal improvements in the second half of the year due to steady growth in R&D investments from the top 30 global pharmaceutical companies [2] - The GLP-1 peptide and small molecule weight loss drug sectors are experiencing high demand, with ample customer orders, while the international situation is expected to stabilize following recent trade negotiations [2] - The anticipated interest rate cuts by the Federal Reserve by 2025 are expected to improve liquidity and revive the global innovative drug industry [2] Group 3 - Focus on the equipment sector's resilience and new technology directions such as AI in healthcare and brain-computer interfaces, as the medical industry faces fewer compliance impacts [3] - The Hang Seng Medical ETF (513060) is highlighted for its efficient layout and strong representation of the medical device, pharmaceutical, and biotechnology sectors, with a low tracking error and high liquidity [3]

Group 1 - The core viewpoint of the article highlights the significant growth in China's innovative drug development pipeline, which accounts for approximately 25% of the global total [1] - The Director of the Drug Registration Management Department of the National Medical Products Administration, Yang Ting, stated that around 3,000 clinical trial projects are conducted annually in China, placing the country among the leaders globally in this area [1] Group 2 - The stock prices of several companies in the pharmaceutical sector, including Boteng Co., Ltd., Kanglong Chemical, and Haitai Biological, saw notable increases, with Boteng Co., Ltd. rising nearly 10% and others rising over 5% [1] - The positive sentiment in the market is likely driven by the announcement regarding China's strong position in innovative drug development and clinical trials [1]

Group 1 - The CXO concept stocks in the Hong Kong market experienced an initial rise, with Kanglong Chemical (300759) increasing by over 10% [1] - Zhaoyan New Drug (603127) saw a rise of over 6%, while WuXi Biologics increased by over 4% [1] - Other companies such as Tigermed (300347) and WuXi AppTec (603259) also followed the upward trend [1] Group 2 - Investors can buy Hong Kong stocks through A-share accounts without the need for the Hong Kong Stock Connect, allowing for T+0 trading [1]

今日涨跌幅居前的概念板块 截至7月23日收盘，CRO概念上涨0.43%，位居概念板块涨幅第6，板块内，35股上涨，美迪西、和元生 物、益诺思等涨幅居前，分别上涨8.83%、8.61%、7.86%。跌幅居前的有诚达药业、四川双马、谱尼测 试等，分别下跌13.12%、6.06%、3.73%。 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 603127 | 昭衍新 药 | 6.43 | 9.22 | 20301.49 | 12.72 | | 688076 | ST诺泰 | 3.72 | 8.35 | 9287.12 | 8.59 | | 000813 | 德展健 康 | 3.57 | 7.73 | 8458.92 | 13.24 | | 300347 | 泰格医 药 | 0.66 | 3.12 | 7741.24 | 7.48 | | 603538 | 美诺华 | 4.20 | 15.91 | 3839.84 | 4.36 ...

Group 1 - The core viewpoint highlights the strong performance of the innovative drug ETFs, with Tianhong Innovative Drug ETF (517380) leading the industry with a 1.89% increase and a total trading volume of 4.6489 million yuan on July 23, 2025 [2] - The Tianhong Innovative Drug ETF has seen a cumulative increase of 3.93% over the past week, indicating positive momentum in the sector [2] - The Biopharmaceutical ETF (159859) also showed a 1.50% increase with a trading volume of 40.8703 million yuan, reflecting strong investor interest [2] Group 2 - The Biopharmaceutical ETF (159859) has achieved a 2.84% increase over the past week, ranking first among comparable funds, with an average daily trading volume of 110 million yuan [3] - The Biopharmaceutical ETF has experienced a significant growth of 543 million yuan in scale over the past year, indicating robust demand [3] - Guotai Junan Securities continues to recommend the innovative drug sector, citing improvements in both domestic and overseas markets, with new insurance directories supporting innovative drug development [3] Group 3 - The collaboration between stable operation of medical insurance funds and optimized centralized procurement policies is positively impacting the innovative drug industry, enhancing patient accessibility and market demand [4] - Recent trends show that multiple pharmaceutical companies are successfully launching innovative drugs overseas, validating China's R&D capabilities [4] - The Tianhong Innovative Drug ETF (517380) is noted as the only ETF tracking the Hang Seng-Hushen-Hong Kong Innovative Drug Select 50 Index, providing comprehensive coverage of A-shares and Hong Kong stocks [4]

Group 1 - The three major indices collectively rose, with the ChiNext Index opening low and then rising, reaching a new high for the year as of July 22, with a gain of 0.43% [1] - The Tianhong ChiNext ETF (159977) increased by 0.63% as of the same date, having gained nearly 19% over the past 60 trading days [1] - The latest circulating share count for the Tianhong ChiNext ETF is 3.626 billion shares, with a circulating scale of 8.692 billion yuan [1] Group 2 - Guotai Junan Securities recommends significantly increasing allocation to the ChiNext board while slightly increasing the allocation to the Sci-Tech Innovation Board and reducing allocation to the main board [2] - There is a notable adjustment in the holding structure of active funds, with increased allocation to mid-cap growth stocks represented by the CSI 500, such as technology hardware, pharmaceuticals, and new consumption [2] - The financial sector's allocation has been significantly increased, particularly in insurance, city commercial banks, and joint-stock banks, aligning with the trend of public fund reforms [2]